INCREASING EVIDENCE FOR THE SAFETY OF FOVEA-INVOLVING HALF-DOSE PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Humans
Central Serous Chorioretinopathy
/ drug therapy
Photosensitizing Agents
/ therapeutic use
Verteporfin
/ therapeutic use
Retrospective Studies
Prospective Studies
Porphyrins
/ therapeutic use
Fluorescein Angiography
Photochemotherapy
/ methods
Chronic Disease
Tomography, Optical Coherence
Randomized Controlled Trials as Topic
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
pubmed:
3
2
2023
medline:
25
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
A retrospective study was performed with data from the prospective randomized controlled trials, PLACE and SPECTRA, assessing the risk of foveal atrophy and the likelihood of structural and functional improvement on optical coherence tomography, after foveal half-dose photodynamic therapy in chronic central serous chorioretinopathy. A total of 57 chronic central serous chorioretinopathy patients received a single half-dose photodynamic therapy with a treatment spot that included the fovea. Optical coherence tomography scans and fundus autofluorescence images were analyzed for structural improvement and possible atrophy development, at baseline and at several visits after treatment. Main outcome measures were integrity of the external limiting membrane and ellipsoid zone on optical coherence tomography and hypoautofluorescence on fundus autofluorescence. The subfoveal external limiting membrane was graded as continuous in 21 of 57 of patients (36.8%) at baseline, and the subfoveal ellipsoid zone was graded as continuous in 5 of 57 patients (8.8%) at first visit, which improved to 50 of 51 (98.0%) and 32 out of 51 (62.7%) at the final visit at 2 years, respectively (both P < 0.001). Hypoautofluorescent changes on fundus autofluorescence were present in 25 of 55 patients (45.5%) at baseline and in 23 of 51 patients (45.1%) at the final visit ( P = 0.480). In patients with chronic central serous chorioretinopathy who received a single, foveal, half-dose photodynamic therapy, a significant improvement in structure and function was seen at the final follow-up. None of the patients developed foveal atrophy.
Identifiants
pubmed: 36727801
doi: 10.1097/IAE.0000000000003686
pii: 00006982-202303000-00002
pmc: PMC9935620
doi:
Substances chimiques
Photosensitizing Agents
0
Verteporfin
0X9PA28K43
Porphyrins
0
Banques de données
ClinicalTrials.gov
['NCT03079141']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
379-388Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Opthalmic Communications Society, Inc.
Références
van Rijssen TJ, van Dijk EHC, Yzer S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 2019;73:100770.
Spaide RF, Gemmy Cheung CM, Matsumoto H, et al. Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res 2022;86:100973.
Brinks J, van Dijk EHC, Meijer OC, et al. Choroidal arteriovenous anastomoses: a hypothesis for the pathogenesis of central serous chorioretinopathy and other pachychoroid disease spectrum abnormalities. Acta Ophthalmol 2022;100:946–959.
Breukink MB, Dingemans AJ, den Hollander AI, et al. Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. Clin Ophthalmol 2016;11:39–46.
van Rijssen TJ, van Dijk EHC, Tsonaka R, et al. Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial. Am J Ophthalmol 2022;233:101–110.
van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology 2018;125:1547–1555.
Lotery A, Sivaprasad S, O'Connell A, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet 2020;395:294–303.
van Dijk EHC, van Rijssen TJ, Subhi Y, Boon CJF. Photodynamic therapy for chorioretinal diseases: a practical approach. Ophthalmol Ther 2020;9:329–342.
Lee PY, Kim KS, Lee WK. Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol 2009;53:52–56.
Piccolino FC, Eandi CM, Ventre L, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003;23:752–763.
Koytak A, Erol K, Coskun E, et al. Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. Retina 2010;30:1698–1703.
Reibaldi M, Cardascia N, Longo A, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 2010;149:307–315 e2.
Mehta PH, Meyerle C, Sivaprasad S, et al. Preferred practice pattern in central serous chorioretinopathy. Br J Ophthalmol 2017;101:587–590.
Sirks MJ, van Dijk EHC, Rosenberg N, et al. Clinical impact of the worldwide shortage of verteporfin (Visudyne ® ) on ophthalmic care. Acta Ophthalmol 2022;100:e1522–e1532.
Feenstra HMA. Crossover to half-dose photodynamic therapy or eplerenone in chronic central serous chorioretinopathy patients (SPECS). Ophthalmol Retina 2022;6:930–938.
van Rijssen TJ, Mohabati D, Dijkman G, et al. Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy. PLoS One 2018;13:e0202549.
Schutze C, Wedl M, Baumann B, et al. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol 2015;159:1100–1114 e1.
Ho M, Lai FHP, Ng DSC, et al. Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy. Br J Ophthalmol 2021;105:555–560.
Nassisi M, Lavia C, Alovisi C, et al. Short-term choriocapillaris changes in patients with central serous chorioretinopathy after half-dose photodynamic therapy. Int J Mol Sci 2017;2018:2468.
Rishi P, Kasinathan N, Sahu C. Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration. Clin Ophthalmol 2011;5:167–170.
Wachtlin J, Behme T, Heimann H, et al. Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2003;241:518–521.
Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001;119:198–207.
Gattoussi S, Cougnard-Gregoire A, Korobelnik JF, et al. Choroidal thickness, vascular factors, and age-related macular degeneration: the ALIENOR Study. Retina 2019;39:34–43.
Cheung CMG, Lee WK, Koizumi H, et al. Pachychoroid disease. Eye (Lond) 2019;33:14–33.
Maruko I, Iida T, Sugano Y, et al. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 2010;117:1792–1799.
Vasconcelos H, Marques I, Santos AR, et al. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2013;251:1697–1705.
Silva RM, Ruiz-Moreno JM, Gomez-Ulla F, et al. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study. Retina 2013;33:309–315.
Wang MS, Sander B, Larsen M. Retinal atrophy in idiopathic central serous chorioretinopathy. Am J Ophthalmol 2002;133:787–793.
van Rijssen TJ, van Dijk EHC, Scholz P, et al. Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy. Graefes Arch Clin Exp Ophthalmol 2021;259:905–910.
Rijssen TJ, Dijk EHC, Scholz P, et al. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. Acta Ophthalmol 2021;99:805–811.